Avishai M Tsur1,2,3, Abdulla Watad1,2, Omer Gendelman1,2, Daniel Nissan4, Arnon D Cohen5,6, Howard Amital1,2,6. 1. Department of Medicine 'B', Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer. 2. Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv. 3. Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan. 4. School of Public Health, Sackler Faculty of Medicine, Tel Aviv University. 5. Chief Physician's Office, Clalit Health Services,Tel-Aviv. 6. Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Abstract
OBJECTIVE: To assess the association between FMF and asthma. METHODS: This study was designed as a cross-sectional study. All patients diagnosed with FMF between 1 January 2000 and 31 December 2016 who were prescribed colchicine were included in the study. Controls were matched by sex, date of birth, residential socioeconomic status and country of birth. Logistic regression models were used to determine the odds ratio for asthma in FMF patients and controls. RESULTS: A total of 7098 FMF patients who were prescribed colchicine were identified. Of them, 3547 (50%) were females, 3632 (51%) were of low residential socioeconomic status and 6160 (87%) were born in Israel. Their median age at the end of follow-up was 37 years (23-54). In an unadjusted logistic regression, FMF was associated with asthma [odds ratio (OR)=1.33, 95% CI: 1.17, 1.51; P <0.001]. The association persisted after adjusting for sex, socioeconomic status and country of birth (OR=1.33, 95% CI: 1.18, 1.52; P <0.001). CONCLUSION: FMF is positively associated with asthma. Further research is required to validate our results and explore possible explanations of this association. These findings cast doubt on previous studies implying FMF to be a protective factor from asthma.
OBJECTIVE: To assess the association between FMF and asthma. METHODS: This study was designed as a cross-sectional study. All patients diagnosed with FMF between 1 January 2000 and 31 December 2016 who were prescribed colchicine were included in the study. Controls were matched by sex, date of birth, residential socioeconomic status and country of birth. Logistic regression models were used to determine the odds ratio for asthma in FMF patients and controls. RESULTS: A total of 7098 FMF patients who were prescribed colchicine were identified. Of them, 3547 (50%) were females, 3632 (51%) were of low residential socioeconomic status and 6160 (87%) were born in Israel. Their median age at the end of follow-up was 37 years (23-54). In an unadjusted logistic regression, FMF was associated with asthma [odds ratio (OR)=1.33, 95% CI: 1.17, 1.51; P <0.001]. The association persisted after adjusting for sex, socioeconomic status and country of birth (OR=1.33, 95% CI: 1.18, 1.52; P <0.001). CONCLUSION: FMF is positively associated with asthma. Further research is required to validate our results and explore possible explanations of this association. These findings cast doubt on previous studies implying FMF to be a protective factor from asthma.
Authors: Avishai M Tsur; Paula David; Abdulla Watad; Daniel Nissan; Arnon D Cohen; Howard Amital Journal: J Gen Intern Med Date: 2022-04-11 Impact factor: 6.473